Loading
HRS9531 injection；Placebo / Overweight and Obesity · Phase 1 Trial
ClinicalTrials.gov · July 31, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an active Phase 1 safety and tolerability trial of HRS9531 injection versus placebo in adolescents with obesity, currently recruiting. No outcomes or efficacy data are available; the registry record describes the planned study only.
Phase 1, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Overweight and Obesity; age from 12 Years; to 18 Years. Intervention: Treatment group A: HRS9531 injection or Placebo; Treatment group B: HRS9531 injection or Placebo; Treatment group C: HRS9531 injection or Placebo. Compared with: Placebo. n = 48. 1 site: China.
This is an active Phase 1 safety and tolerability trial of HRS9531 injection versus placebo in adolescents with obesity, currently recruiting. No outcomes or efficacy data are available; the registry record describes the planned study only.
Pharmacokinetics and pharmacodynamics endpoints mentioned in brief summary but not detailed in primary outcome measures list. No efficacy data available; only safety and tolerability endpoints are planned.
The source did not state who this applies to in practice.
Phase 1 trial in recruitment with no results posted; establishes only planned design and safety endpoints in adolescents with obesity.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07559136). This is a study registration, not published results. Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 48 participants (ESTIMATED). Conditions: Overweight and Obesity. Interventions: DRUG: HRS9531 injection；Placebo; DRUG: HRS9531 injection；Placebo; DRUG: HRS9531 injection；Placebo. Primary outcome measures: Adverse Events (AEs) , up to Week 28. Brief summary: The aim of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS9531 injection compared with placebo in adolescents with obesity
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.